CL2023001797A1 - Anticuerpos biespecíficos contra ceacam5 y cd47 - Google Patents

Anticuerpos biespecíficos contra ceacam5 y cd47

Info

Publication number
CL2023001797A1
CL2023001797A1 CL2023001797A CL2023001797A CL2023001797A1 CL 2023001797 A1 CL2023001797 A1 CL 2023001797A1 CL 2023001797 A CL2023001797 A CL 2023001797A CL 2023001797 A CL2023001797 A CL 2023001797A CL 2023001797 A1 CL2023001797 A1 CL 2023001797A1
Authority
CL
Chile
Prior art keywords
bispecific antibodies
relates
antibodies
antibodies against
ceacam5
Prior art date
Application number
CL2023001797A
Other languages
English (en)
Inventor
BUATOIS Vanessa
Seckinger Anja
HOSE Dirk
Original Assignee
Lamkap Bio Beta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lamkap Bio Beta Ltd filed Critical Lamkap Bio Beta Ltd
Publication of CL2023001797A1 publication Critical patent/CL2023001797A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pens And Brushes (AREA)
  • Conversion Of X-Rays Into Visible Images (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano CEACAM5 y a CD47 humana. Además, la presente invención se refiere a polinucleótidos que codifican para estos anticuerpos biespecíficos y vectores y células hospedadoras que comprenden estos polinucleótidos. La invención se refiere además a métodos para seleccionar y producir estos anticuerpos y a métodos para usar estos anticuerpos en el tratamiento de enfermedades. La invención también se refiere al uso terapéutico de los anticuerpos biespecíficos en monoterapia y en terapia de combinación.
CL2023001797A 2020-12-18 2023-06-16 Anticuerpos biespecíficos contra ceacam5 y cd47 CL2023001797A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20215766 2020-12-18
US202163135996P 2021-01-11 2021-01-11

Publications (1)

Publication Number Publication Date
CL2023001797A1 true CL2023001797A1 (es) 2024-02-09

Family

ID=79164846

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001797A CL2023001797A1 (es) 2020-12-18 2023-06-16 Anticuerpos biespecíficos contra ceacam5 y cd47

Country Status (16)

Country Link
US (2) US11753481B2 (es)
EP (1) EP4055055B1 (es)
JP (1) JP2024501809A (es)
KR (1) KR20230121772A (es)
AU (1) AU2021400227A1 (es)
CA (1) CA3193210A1 (es)
CL (1) CL2023001797A1 (es)
CO (1) CO2023009100A2 (es)
ES (1) ES2967381T3 (es)
HR (1) HRP20240213T1 (es)
IL (1) IL301701A (es)
MX (1) MX2023007220A (es)
PE (1) PE20231386A1 (es)
PL (1) PL4055055T3 (es)
RS (1) RS65211B1 (es)
WO (1) WO2022130348A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566938A (zh) * 2018-06-03 2021-03-26 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体
IL301701A (en) 2020-12-18 2023-05-01 Lamkap Bio Beta Ag Bispecific antibodies against CEACAM5 and CD47
US20240002544A1 (en) * 2022-03-07 2024-01-04 Novimmune Sa Cd28 bispecific antibodies for targeted t cell activation
WO2023242351A1 (en) 2022-06-16 2023-12-21 Lamkap Bio Beta Ag Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294372B1 (en) 1997-03-14 2001-09-25 University Of Victoria Innovation & Dev. Corp. Replication genes and gene products from small cryptic plasmids and methods for constructing controlled-replication plasmid vectors
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2003265522A1 (en) 2003-08-18 2005-03-10 Macrogenics, Inc. FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
CA2548817A1 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
KR101297146B1 (ko) 2004-05-10 2013-08-21 마크로제닉스, 인크. 인간화 ＦｃγＲＩＩＢ 특이적 항체 및 그의 사용 방법
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
EP1919950A1 (en) 2004-07-15 2008-05-14 Xencor, Inc. Optimized fc variants
CA2577329A1 (en) 2004-08-16 2006-03-02 Medimmune, Inc. Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
WO2006116260A2 (en) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
AU2006268227A1 (en) 2005-07-08 2007-01-18 Xencor, Inc Optimized anti-Ep-CAM antibodies
US8217147B2 (en) 2005-08-10 2012-07-10 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗ｃｄ３０抗体
JP5328019B2 (ja) 2005-10-21 2013-10-30 レヴォ バイオロジクス インコーポレイテッド 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法
PL1976880T3 (pl) 2005-12-21 2017-01-31 Amgen Research (Munich) Gmbh Kompozycje farmaceutyczne odporne na rozpuszczalny cea
EP1999470A4 (en) 2006-03-10 2009-08-19 Macrogenics Inc IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
IL177158A0 (en) 2006-07-30 2008-01-20 Assaf Klar Method for designing and implementing improved longitudinal flexibility multilayered pipeline
PT2059536E (pt) 2006-08-14 2014-04-14 Xencor Inc Anticorpos otimizados que visam cd19
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
WO2008121160A2 (en) 2006-11-21 2008-10-09 Xencor, Inc. Optimized antibodies that target cd5
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
WO2008091798A2 (en) 2007-01-22 2008-07-31 Xencor, Inc. Optimized ca9 antibodies and methods of using the same
AU2008207898B2 (en) 2007-01-23 2012-05-03 Xencor, Inc Optimized CD40 antibodies and methods of using the same
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
WO2008098115A2 (en) 2007-02-07 2008-08-14 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
EP2708557A1 (en) 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
RS54233B1 (en) 2008-08-25 2015-12-31 Amplimmune Inc. PD-1 ANTAGONIST COMPOSITIONS AND PROCEDURES FOR THEIR APPLICATION
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
EP2331578B1 (en) 2008-09-17 2014-06-04 Xencor, Inc. Novel compositions and methods for treating ige-mediated disorders
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
CN102482701B (zh) 2009-09-16 2015-05-13 免疫医疗公司 I类抗-cea抗体及其使用
MY160680A (en) 2009-09-22 2017-03-15 Probiogen Ag Process for producing molecules containing specialized glycan structures
ES2537207T3 (es) 2010-08-16 2015-06-03 Novimmune S.A. Métodos para la generación de anticuerpos multiespecíficos y multivalentes
SI2681244T1 (en) 2011-03-02 2018-03-30 Roche Glycart Ag PROTITELESA CEA
WO2013012414A1 (en) 2011-07-18 2013-01-24 Medimmune, Llc Dosing regimens for treatment of cea-expressing cancers
TW201840336A (zh) 2011-08-01 2018-11-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
JP6435193B2 (ja) 2011-10-19 2018-12-05 ノビミューン エスアー 抗体を精製する方法
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
CN104470949A (zh) 2012-05-15 2015-03-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
EP2925782B1 (en) 2012-12-03 2020-01-22 NovImmune SA Anti-cd47 antibodies and methods of use thereof
EP2945969A1 (en) 2013-01-15 2015-11-25 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
KR101833602B1 (ko) 2013-02-26 2018-02-28 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
MX2015010843A (es) 2013-02-26 2016-04-04 Roche Glycart Ag Moleculas biespecificas de union al antigeno que activan celulas t.
ES2827679T3 (es) 2013-08-20 2021-05-24 Merck Sharp & Dohme Tratamiento del cáncer con una combinación de un antagonista de PD-1 y dinaciclib
EP3096782A4 (en) 2014-01-21 2017-07-26 Medlmmune, LLC Compositions and methods for modulating and redirecting immune responses
WO2016007235A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
AU2016239683B2 (en) 2015-03-31 2022-02-03 Novimmune Sa Method for optimizing the assembly and production of hetero-multimeric protein complexes
BR112018000835A2 (pt) 2015-10-02 2018-09-11 Hoffmann La Roche molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
GB2546072B (en) 2016-01-05 2019-07-10 Bja Trading Ltd Attachment assembly and method of using same
CA3006529A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
TW201741340A (zh) 2016-05-09 2017-12-01 賽基公司 Cd47抗體及使用其之方法
EP3515936A1 (en) 2016-09-23 2019-07-31 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
WO2018098384A1 (en) 2016-11-22 2018-05-31 Regents Of The University Of California Segregation modulation for immunotherapy
US11518810B2 (en) 2017-05-08 2022-12-06 Shanghai Jmt-Bio Technology Co., Ltd. Bispecific recombinant protein and use thereof
CN111201238B (zh) 2017-07-21 2023-09-08 诺夫免疫股份有限公司 产生多特异性抗体混合物及其使用方法
CN112566938A (zh) 2018-06-03 2021-03-26 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
IL301701A (en) 2020-12-18 2023-05-01 Lamkap Bio Beta Ag Bispecific antibodies against CEACAM5 and CD47

Also Published As

Publication number Publication date
JP2024501809A (ja) 2024-01-16
RS65211B1 (sr) 2024-03-29
KR20230121772A (ko) 2023-08-21
US20240101705A1 (en) 2024-03-28
CO2023009100A2 (es) 2023-08-18
EP4055055B1 (en) 2023-11-22
WO2022130348A1 (en) 2022-06-23
EP4055055A1 (en) 2022-09-14
HRP20240213T1 (hr) 2024-04-26
MX2023007220A (es) 2023-08-25
IL301701A (en) 2023-05-01
ES2967381T3 (es) 2024-04-30
US11753481B2 (en) 2023-09-12
EP4055055C0 (en) 2023-11-22
PL4055055T3 (pl) 2024-04-15
AU2021400227A1 (en) 2023-04-27
US20220195067A1 (en) 2022-06-23
PE20231386A1 (es) 2023-09-12
CA3193210A1 (en) 2022-06-23
AU2021400227A9 (en) 2024-05-30

Similar Documents

Publication Publication Date Title
CO2023009100A2 (es) Anticuerpos biespecíficos contra ceacam5 y cd47
CO2022004685A2 (es) Anticuerpos biespecificos contra ceacam5 y cd3
CL2023000907A1 (es) Anticuerpos de unión a gprc5d
MX2020013122A (es) Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47).
CL2021001506A1 (es) Anticuerpos que se unen a cd3
NI201900005A (es) Anticuerpos anti-gprc5d, molã‰culas de uniã“n a antãgeno bispecãfico que unen a gprc5d y cd3, y sus usos
CY1122858T1 (el) Cd123 δεσμευοντες παραγοντες και χρησεις αυτων
CO2018001524A2 (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estos
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
CY1119112T1 (el) K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος
AR119553A1 (es) Anticuerpos que se fijan a gprc5d
EA201891084A1 (ru) Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
PE20221326A1 (es) Anticuerpos anti-mertk y metodos de uso de los mismos
CL2020002446A1 (es) Anticuerpos contra mica y/o micb y sus usos
PE20210708A1 (es) Anticuerpos especificos para cd70 y sus usos
CO2023000057A2 (es) Anticuerpos que se unen a cd3 y cd19
AR122658A1 (es) Anticuerpos que se unen a cd3
AR036833A1 (es) Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular.
CL2021000146A1 (es) Anticuerpos humanizados contra psma
ECSP20039728A (es) Anticuerpos monoclonales y métodos para utilizar los mismos
PE20201149A1 (es) Anticuerpos de union a hla-a2/wt1
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
CO2021008204A2 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso
CO2019010164A2 (es) Anticuerpos que se unen a steap-1